Target intelligence / Profile preview

House dust mite allergen-specific immunoglobulin E antibody (HDM allergen-specific IgE (occasionally sIgE))

Target
HDM allergen-specific IgE (occasionally sIgE)
Molecular classification
Antibody (immunoglobulin E isotype), Other (adaptive immune effector molecule)
01

Overview

House dust mite allergen-specific immunoglobulin E antibody (HDM-specific IgE) is an adaptive immune antibody (IgE class) produced by B cells after sensitization to dust mite allergens, primarily Der p 1, Der f 1, and related proteins. These antibodies bind tightly to high-affinity IgE receptors (FcεRI) on mast cells and basophils in tissues, sensitizing these cells. On re-exposure to the allergen, crosslinking of bound IgE by allergens results in cell degranulation, releasing histamine, leukotrienes, and other mediators responsible for allergic symptoms. The presence and level of HDM-specific IgE in serum are central biomarkers for allergy diagnosis, monitoring, and patient selection for allergen immunotherapy. Anti-IgE drugs (e.g., omalizumab) can suppress the allergic response by neutralizing IgE.

Other names
Allergen-specific IgEHDM-specific IgEDust mite allergy IgEsIgE to HDMHouse dust mite-specific IgE
02

Mechanism of action

Anti-IgE drugs bind and neutralize free IgE, preventing binding to FcεRI and subsequent activation of effector cells

03

Biological functions

Mediates type I hypersensitivity reactionsInitiates allergic immune responses to dust mite allergensBinds high-affinity IgE receptors (FcεRI) on mast cells and basophilsFacilitates allergen-induced mast cell/basophil degranulation
04

Disease associations

Allergic rhinitisAsthmaAtopic dermatitisOther IgE-mediated allergies
05

Safety considerations

IgE antibody depletion may impair defense against helminth infections or cause immune modulationRisk of hypersensitivity reactions during immunotherapy
06

Interacting drugs

Omalizumab (and other anti-IgE monoclonal antibodies)
07

Biomarkers

Serum house dust mite-specific IgE level (for sensitization diagnosis, therapy monitoring, patient selection for immunotherapy)

Beyond the preview

Go deeper on House dust mite allergen-specific immunoglobulin E antibody (HDM allergen-specific IgE (occasionally sIgE)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on House dust mite allergen-specific immunoglobulin E antibody (HDM allergen-specific IgE (occasionally sIgE)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call